See more : Icade SA (CDMGF) Income Statement Analysis – Financial Results
Complete financial analysis of 9 Meters Biopharma, Inc. (NMTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 9 Meters Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zabka Group S.A. (ZAB.WA) Income Statement Analysis – Financial Results
- Euromedis Groupe (ALEMG.PA) Income Statement Analysis – Financial Results
- Armada Hoffler Properties, Inc. (AHH) Income Statement Analysis – Financial Results
- IRM Energy Limited (IRMENERGY.NS) Income Statement Analysis – Financial Results
- Compass Group PLC (CMPGF) Income Statement Analysis – Financial Results
9 Meters Biopharma, Inc. (NMTR)
About 9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.88M | 4.07M | 8.27M | 11.34M | 3.44M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95M | 3.33M | 7.84M | 11.11M | 2.84M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -64.00K | 736.00K | 426.00K | 234.00K | 606.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.40% | 18.11% | 5.15% | 2.06% | 17.60% |
| Research & Development | 31.01M | 22.00M | 10.93M | 13.72M | 7.56M | 190.00K | 270.00K | 333.00K | 542.00K | 709.00K |
| General & Administrative | 11.01M | 9.66M | 10.52M | 10.57M | 10.66M | 4.98M | 3.98M | 3.63M | 2.65M | 1.75M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.43M | 2.43M | 2.93M | 3.72M | 1.52M |
| SG&A | 11.01M | 9.66M | 10.52M | 10.57M | 10.66M | 6.41M | 6.41M | 6.55M | 6.37M | 3.26M |
| Other Expenses | 0.00 | 5.10B | 39.42B | 1.27B | 0.00 | 920.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 42.02M | 31.66M | 21.45M | 24.28M | 18.22M | 6.60M | 6.68M | 6.89M | 6.91M | 3.97M |
| Cost & Expenses | 42.02M | 31.66M | 21.45M | 24.28M | 18.22M | 8.55M | 10.01M | 14.73M | 18.02M | 6.81M |
| Interest Income | 501.23K | 22.71K | 18.99K | 185.27K | 163.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.67M | 47.19K | 4.05M | 1.83M | 6.15M | 93.00K | 825.00K | 1.38M | 1.66M | 66.00K |
| Depreciation & Amortization | 509.75K | 5.13M | 39.46M | 1.47M | 19.56K | 131.00K | 131.00K | 54.00K | -2.47M | 606.00K |
| EBITDA | -41.51M | -31.63M | -21.42M | -24.08M | -18.04M | -5.62M | -5.81M | -7.30M | -9.38M | -3.37M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -298.19% | -142.98% | -88.36% | -82.72% | -97.71% |
| Operating Income | -42.02M | -36.76M | -60.88M | -25.55M | -18.22M | -8.89M | -6.68M | -6.89M | -6.91M | -3.97M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -472.01% | -164.31% | -83.31% | -60.92% | -115.30% |
| Total Other Income/Expenses | -1.75M | -17.48K | 60.82B | -1.50M | -5.94M | 963.00K | 468.00K | -1.85M | -4.13M | 540.00K |
| Income Before Tax | -43.77M | -36.78M | -61.50M | -27.05M | -24.16M | -7.93M | -6.21M | -8.74M | -11.04M | -3.43M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -420.87% | -152.79% | -105.72% | -97.36% | -99.62% |
| Income Tax Expense | 1.75M | 47.19K | 4.05M | 1.83M | 213.83K | 1.01M | 2.00K | 2.00K | 13.00K | 4.00K |
| Net Income | -45.52M | -36.83M | -65.54M | -28.87M | -24.16M | -7.93M | -6.21M | -8.74M | -11.06M | -3.44M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -420.87% | -152.84% | -105.75% | -97.48% | -99.74% |
| EPS | -3.51 | -3.03 | -12.41 | -17.33 | -19.52 | -13.33 | -225.11 | -330.66 | -416.15 | -129.94 |
| EPS Diluted | -3.51 | -3.03 | -12.41 | -17.33 | -19.52 | -13.33 | -225.11 | -328.98 | -416.15 | -129.28 |
| Weighted Avg Shares Out | 12.96M | 12.16M | 5.28M | 1.67M | 1.24M | 594.41K | 27.60K | 26.44K | 26.57K | 26.44K |
| Weighted Avg Shares Out (Dil) | 12.96M | 12.16M | 5.28M | 1.67M | 1.24M | 594.41K | 27.60K | 26.57K | 26.57K | 26.57K |
Drug developer 9 Meters Biopharma files for bankruptcy protection
Drug developer 9 Meters Biopharma and its units have filed for Chapter 11 bankruptcy protection, it said in a regulatory filing on Tuesday, sending its shares tumbling 66% in premarket trading.
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9...
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9...
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced two poster presentations at the American College of Gastroenterology (ACG) 2022...
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.
How to Find Trending Penny Stocks in 2022
Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What to Know About Buying Penny Stocks on June 24th
Here's what you need to know about trading penny stocks on June 24th The post What to Know About Buying Penny Stocks on June 24th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What to Know About Buying Penny Stocks on June 23rd
Here's what you need to know about trading penny stocks on June 23rd The post What to Know About Buying Penny Stocks on June 23rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Are 9 Meters Biopharma Shares Plunging Today?
9 Meters Biopharma Inc (NASDAQ: NMTR) completed a pre-specified interim analysis for the Phase 3 study of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet. Based on consultation with the independent.
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9...
Source: https://incomestatements.info
Category: Stock Reports